Remix: targeting RNA modulating complexes
Emerging Company Profile: Remix is using its REMaster platform to identify and validate RNA processing targets
Start-up Remix aims to use its $81 million in seed and series A funding to correct disease-causing RNA dysregulation.
President and CSO Peter Smith founded Remix Therapeutics Inc. last year as an entrepreneur in residence at Atlas Ventures after surveying the emerging literature about mechanisms of RNA processing and how they are dysregulated in a variety of diseases. ...